Abstract. Novel agents need to be developed to overcome the limitations of the current melanoma therapeutics. Atractylenolide I (AT-I) is a sesquiterpene compound isolated from atractylodis macrocephalae rhizoma. Previous findings demonstrated that AT-I exhibited cytotoxic action in melanoma cells. However, the molecular mechanisms of AT-1's anti-melanoma properties remain to be elucidated. In the present study, the cell cycle-arrest and apoptosis-promoting effects as well as the ERK/GSK3β signaling-related mechanism of action of AT-I were examined. B16 melanoma cells were treated with various concentrations of AT-1 (50, 75 and 100 µM) for 48 or 72 h. Cell cycle and apoptosis were analyzed by flow cytometry. Protein expression levels were detected by western blot analysis. AT-I treatment induced G1 phase arrest, which was accompanied by increased p21 and decreased CDK2 protein expression levels. Apoptosis was observed after AT-I treatment for 72 h, which was accompanied by activated caspase-3 and -8. AT-I treatment significantly decreased phospho-ERK, phospho-GSK3β, c-Jun and increased p53 protein expression levels. Lithium chloride (LiCl, 5 mM), a GSK3β inhibitor, treatment alone did not increase the apoptosis of B16 cells, while pretreatment with LiCl markedly reversed AT-I-induced apoptosis. Additionally, AT-I-induced G1 phase arrest was partially reversed by LiCl pretreatment. In conclusion, ERK/GSK3β signaling was involved in the apoptotic and G1 phase arrest effects of AT-I in melanoma cells.
Introduction
Malignant melanoma is a potentially lethal form of skin cancer. Although it accounts for <2% of all skin cancer cases, it is responsible for ~75% of all mortality from skin cancer (1) . Two targeted therapeutic agents (ipilimumab and vemurafenib) have shown promise in the survival rates in patients with advanced melanoma (2) (3) (4) . However, the majority of patients who respond to the targeted therapies eventually develop resistance and disease progression (5) . Novel agents need to be developed to overcome the limitations of the current therapeutic agents.
Medical plants have been considered a valuable source of bioactive compounds for the treatment of many conditions, including cancer (6) . Atractylodis macrocephalae rhizoma (Baizhu in Chinese) is a traditional Chinese medicinal herb. The extracts of Baizhu exhibited various pharmacological activities, such as anti-inflammation (7), anti-lipid-peroxidation (8) and antitumor activities (9, 10) . In a previous study, we isolated eight sesquiterpene compounds from Baizhu and evaluated their anti-melanoma properties (11) . The MTT data demonstrated that atractylenolide I (AT-I) was one of the major active components, which displayed cytotoxic action in melanoma cells (11) . We also observed that AT-I inhibited the activation of ERK in melanoma cells (11) . However, the molecular mechanisms of AT-I anti-melanoma properties remain to be elucidated.
P53 is a major tumor suppressor. Increased p53 activity is associated with cell cycle arrest, through increased expression of p21 (12) and the induction of apoptosis via the intrinsic and extrinsic pathways (13) . Glycogen synthase kinase-3β (GSK3β) has been identified as a major regulator of p53 localization and expression (14, 15) . Activation of GSK3β promoted responses to p53 including increases in the p21 expression level and caspase 3 activity (14, 15) . Pharmacological inhibition of GSK3β activity produced marked reductions in the activation of Bax and caspase 3 and in cell death (14, 15 c-Jun has been reported to directly repress p53 transcription by binding to a variant AP-1 site in the p53 promoter (16) . In cells absent of c-Jun, the expression of p53 and p21 is increased, and those cells exhibit cell cycle arrest (16) . Overexpression of c-Jun in cells results in decreased levels of p53 and p21, and exhibits accelerated cell proliferation (16) . In melanoma cells, activation of ERK can inactivate GSK3β, which in turn increases c-Jun stability and decreases p53 activity (17) .
In the present study, the cell cycle-arrest and apoptosispromoting effects as well as the ERK/GSK3β signaling-related mechanism of action of AT-I were investigated.
Materials and methods
Reagents and antibodies. AT-I was isolated from Baizhu. The purity of the isolated AT-I was determined to be >98% by HPLC (Fig. 1) . Stock solutions of AT-I (100 mM) were prepared in dimethyl sulfoxide (DMSO). Cleaved caspase-3 and -8, p21, cdk2, phospho-ERK (p-ERK, thr202/tyr204), ERK, p-GSK3β (ser9), c-Jun and p-p53 (ser15) antibodies were obtained from Cell Signaling Technology (Beverly, MA, uSA). Caspase-3 and -8, p53, β-actin antibodies and anti-mouse and anti-rabbit IgG antibodies (horseradish peroxidase-conjugated) were purchased from Santa Cruz Biotechnology (Dallas, TX, uSA). Ribonuclease (RNase A), trypsin, propidium iodide (PI) and lithium chloride (LiCl) were purchased from Sigma-Aldrich (St. Louis, MO, uSA). The Annexin V-FITC Apoptosis Detection kit was obtained from BD Biosciences (San Jose, CA, uSA).
HPLC analysis. HPLC analysis was performed in an Agilent 1100 system equipped with a diode-array detector. Solvents for HPLC analysis were HPLC grade. Experimental conditions were summarized as follows: 1 mg of AT-I was prepared in 1 ml methanol. The separation was performed on Synergi Fursion-RP C18 column (250x4.6 mm, 4 µm) with acetonitrilewater (40:60) as the mobile phase. The column temperature was maintained at 30˚C. The flow rate was 1.0 ml/min and the detection wavelength was set at 220 nm.
Cell culture. Murine melanoma B16 cells (Shanghai Branch, Chinese Academy of Sciences, Shanghai, China) were grown in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (all from Gibco, Grand Island, NY, USA). The cells were cultured at 37˚C in a humidified atmosphere of 5% CO 2 .
Determination of cell cycle distribution. The distribution of cells in various phases was determined from DNA content assessed by flow cytometry. Cells were seeded at a density of 4x10 5 in 60-mm dish and grown overnight. Various concentrations of AT-I (50, 75 and 100 µM) and/or 5 mM LiCl were added and the cells were incubated for 48 h. Detached and adherent cells were collected and centrifuged at 300 x g for 5 min at 4˚C. Pellets were rinsed with ice-cold phosphate-buffered saline (PBS) and fixed with ice-cold 70% ethanol overnight. The cells were then stained with staining buffer (PBS containing 20 µg/ml of PI, 100 µg/ml RNase A, and 0.1% Triton X-100) for 30 min at 37˚C in the dark. Stained cells were analyzed using a FACSCalibur™ flow cytometer (BD Biosciences). Western blot analysis. The cells were treated as mentioned above and collected. The proteins were extracted with RIPA lysis buffer [50 mM Tris-Cl, 1% v/v NP-40, 0.35% w/v sodium-deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM NaF and 1 mM Na 3 VO 4 , pH adjusted to 7.4] containing a protease inhibitor cocktail (Roche, Mannheim, Germany) for 15 min at 4˚C. After centrifugation at 12,000 x g for 15 min at 4˚C, the supernatant was collected and regarded as whole cell extract. The protein concentration was determined by a Bio-Rad protein assay (Bio-Rad, Hercules, CA, uSA). Equal amounts of individual protein samples were separated by SDS-PAGE and then electro-transferred onto nitrocellulose membranes (Amersham Biosciences, Piscataway, NJ, uSA). The membranes were blocked for 60 min with 5% skimmed milk in TBST buffer composed of 50 mM Tris (pH 7.6), 150 mM NaCl and 0.1% Tween-20 and incubated with the primary antibodies overnight at 4˚C. β-actin was used as the loading control. After incubation with secondary antibodies (1:2,000), ECL detection reagents (Amersham Biosciences) were used to detect signals. Statistical analysis. Results were presented as the mean ± SD of three independent experiments. Data analysis was performed by one-way analysis of variance (ANOVA). For comparison of two groups, the Student's t-test was used. P<0.05 was considered statistically significant.
Results

AT-I induces cell cycle arrest in B16 cells.
Cell cycle distribution analysis demonstrated that AT-I treatment for 48 h at the concentrations of 50, 75 and 100 µΜ caused a dose-dependent delay of cell cycle progression from G1 to S phase ( Fig. 2A) . Fig. 2B shows the quantified cell distributions in different phases (P<0.01 or P<0.05). These results suggested that AT-I treatment induced G1 phase arrest in B16 cells. The cyclin E-CDK2 complex has a critical role in the G1/S phase transition and it can be directly inhibited by p21 (18) . As demonstrated by western blot assays (Fig. 2C) , AT-I treatment markedly decreased the expression levels of CDK2 and increased the expression levels of p21.
AT-I induces apoptosis in B16 cells.
To investigate whether AT-I induced apoptosis, we analyzed Annexin V/PI-stained B16 cells by flow cytometry. Treatment with 100 µΜ AT-I for 48 h did not induce significant apoptosis in B16 cells (data not shown), while AT-I treatment for 72 h dose-dependently increased late (Q2 in Fig. 3A ) and early stage apoptotic cells (Q4 in Fig. 3A ). Fig. 3B shows the statistical results of total apoptotic cells from three independent experiments. Caspases-3 and -8 are situated at pivotal junctions in apoptosis pathways. Western blot assays demonstrated that treatment with AT-I markedly activated caspase-3 and -8, as evidenced by decreased expression levels of the procaspases and increased expression levels of the cleaved caspases (Fig. 3C) .
AT-I decreases ERK and c-Jun activation but increases
GSK3β and p53 activation in B16 cells. In melanoma, constitutive activation of ERK can inactivate GSK3β, which in turn increases c-Jun stability and decreases p53 activity (14, 17, 19) .
As demonstrated by the western blot assays, AT-I treatment markedly decreased the expression levels of p-ERK and c-Jun, while the expression levels of phospho-p53 and p53 were significantly increased, as compared with the medium control (Fig. 4) . Phosphorylation of GSK-3β at ser9 leads to inactivation of GSK3β (20) . Western blot assays showed that AT-I treatment activated GSK3β, as evidenced by decreased expression levels of p-GSK3β (ser9) (Fig. 4) . (20) . It has been reported that LiCl could counteract cisplatin-induced apoptosis of cancer cells (21, 22) . As demonstrated by the flow cytometric analysis, LiCl (5 mM) treatment alone did not increase the apoptosis of B16 cells, while pretreatment with LiCl (5 mM) significantly reversed AT-I (100 µM)-induced apoptosis (Fig 5A and B) . The cell cycle distribution analysis showed that LiCl (5 mM) pretreatment partially reversed AT-I (100 µM)-induced G1 phase arrest (Fig. 5C ).
LiCl pretreatment reverses AT-I-induced apoptosis and G1 phase arrest. LiCl is a GSK3β inhibitor
Discussion
Malignant melanoma is a lethal skin cancer. Although mutant BRAF-targeted therapy and immunotherapy show promising clinical response, available chemotherapeutics often carry a low response rate, tolerance, high price and/or toxicity (23) . Novel agents need to be developed to overcome the limitations of the current therapeutic agents. In the present study, we reported that AT-I, isolated from the Chinese medicinal herb Baizhu, induced G1 phase arrest and apoptosis in B16 melanoma cells by regulating the ERK/GSK3β signaling pathway.
Progression of cells from G1 to S phase requires the coordination of a group of regulatory proteins. Among the regulators, p53 is well characterized. As a transcriptional factor, p53 can regulate the transcription of p21, which plays a crucial role in G1 phase arrest (12, 24) . P21 binds to the cyclin E-CDK2 complex and inhibits the kinase activity of CDK, thereby inducing cell cycle arrest (25, 26) . In the present study, we observed that the G1 phase-arresting activity of AT-I was accompanied by increased expression levels of phosphop53, p53 and p21, and decreased expression levels of CDK2, suggesting that the p53/p21 pathway may contribute to the G1 phase-arresting activity of AT-I.
Apoptosis is triggered through the extrinsic and intrinsic pathways. The extrinsic pathway involves engagement of particular death receptors that belong to the tumor necrosis factor receptor (TNF-R) family and through the formation of the death-inducing-signaling-complex (DISC), and leads to a cascade of activation of caspases, including caspase-3 and -8 (27) . It is well documented that caspase 8 may be activated by p53 (13) . In our investigations, AT-I treatment-induced apoptosis was associated with p53, and caspase-3 and -8 activation. These findings reveal that activation of the p53/caspase 8 pathway may be involved in the apoptosis-promoting effect of AT-I.
It has been reported that c-jun directly represses p53 transcription by binding to a variant AP-1 site in the p53 promoter (16) . In the present study, AT-1 treatment significantly decreased the expression levels of c-Jun. c-Jun regulates the cell cycle progression via direct transcriptional control of cyclin D1 (28) . The present results show that AT-I treatment decreased the mRNA levels of cylin D1 (data not shown). p53 and c-Jun can be regulated by GSK3β (12, 13, 17) . Classically, GSK3β has been described as a key regulator of glycogen metabolism and is also known to regulate other processes, such as apoptosis, cell proliferation, cell motility and Wnt signaling (28, 29) . Phosphorylation at tyrosine 216 enhances the enzymatic activity of GSK3β, while phosphorylation at serine 9 significantly decreases the activity of GSK3β (30) . In the present study, AT-I treatment significantly activated GSK3β, which is evidenced by the decrease of p-GSK3β (ser9). LiCl can inhibit GSK3β activity by increasing GSK3β phosphorylation at serine 9 (20) . Recent findings suggest that LiCl may counteract the cisplatin-induced apoptosis of cancer cells (21, 22) . In our investigations, pretreatment with LiCl significantly reversed AT-I-induced apoptosis. Additionally, AT-I-induced G1 phase arrest was partially reversed by LiCl. AT-I-induced decreases of cyclin D1 mRNA were also reversed by LiCl (data not shown). These findings suggest that GSK3β signaling may be involved in the apoptosis-promoting and G1 phase-arrest effects of AT-I. In melanoma, the constitutive activation of ERK has been reported to inactivate GSK3β (17) . In the present study, AT-I treatment dose-dependently inhibited ERK activity, suggesting that AT-I may regulate GSK3 signaling through inactivation of ERK.
AT-І reduces the symptoms of patients with gastric cancer cachexia without overt toxicity, slight nausea and dry mouth are the only reported side effects (31, 32) . In rats, AT-I can be rapidly absorbed with a T 1/2α of 0.92 h and is eliminated gradually with a T 1/2β of 9.74 h after intragastric (i.g.) administration (33) , suggesting a good oral bioavailability. We have shown that AT-I can induce cell differentiation, inhibit cell migration and inhibit the phosphorylation of Akt in melanoma cells (11) . Moreover, in the present study we found that AT-I induced G1 phase arrest and apoptosis and inhibited ERK/GSK3β signaling in melanoma cells. Thus further investigations are required to develop AT-I as a pharmaceutical agent for melanoma prevention and/or treatment, although it does not exhibit potent cytotoxic effect.
In conclusion, we have demonstrated the G1 phasearresting and apoptosis-promoting effects and revealed the ERK/GSK3β signaling-related mechanism of action of AT-I in B16 cells. The results of the present study shed light on the molecular mechanisms of AT-1's anti-melanoma properties.
